Gurnet Point Capital
VC Fund
Cambridge, United States
Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economicvalue, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com
- Total investments:
- 19
- Last investment:
- Lead investor:
- 53%
- Fund size:
- $1.5B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Gurnet Point Capital invests in
Stages Gurnet Point Capital invests in
Countries Gurnet Point Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Moore
|
|||
Michael Vigilante
|
|||
Alex Tsoukas
|
|||
|
Anne Stone
|
|||
|
Ernesto Bertarelli
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 7 (37%)
- Biotechnology 6 (32%)
- Medical 4 (21%)
- Pharmaceutical 4 (21%)
- Therapeutics 3 (16%)
Stage
- Series A 4 (21%)
- Funding Round 4 (21%)
- Series B 2 (11%)
- Series C 2 (11%)
- Private Equity 2 (11%)
Country
- United States 9 (47%)
- Switzerland 2 (11%)
- Israel 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Moore
Partner
|
Partner | Total investments: 1 | Find email | |
|
Michael Vigilante
Principal
|
Principal | Total investments: 0 | Find email | |
|
Alex Tsoukas
Principal
|
Principal | Total investments: 1 | Find email | |
|
Anne Stone
Principal
|
Principal | Total investments: 0 | Find email | |
|
Ernesto Bertarelli
Founder
|
Founder | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Corium
|
Corium offers the development and commercialization of central nervous system healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. | Private Equity / Oct 20, 2022 | |
Naveris
|
Naveris is a biotechnology company that provides highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission. The company's 3D biomimetic technology replicates themorphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, its technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts. | $33.4M / Series A / Sep 19, 2022 | |
|
Naveris
|
Naveris is a biotechnology company that provides highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission. The company's 3D biomimetic technology replicates themorphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, its technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts. | $33.4M / Series A / Sep 19, 2022 | |
Alladapt Immunotherapeutics
|
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens. | $119M / Venture - Series Unknown / Jun 22, 2022 | |
Fairtility
|
Fairtility develops solutions that use AI & big data to significantly increase the efficiency of IVF. | $15M / Series A / May 23, 2022 | |
Mahana Therapeutics
|
Mahana Therapeutics develops digital treatments for people living with chronic health conditions that are designed to provide physical and psychological support that will be clinically proven to help patients feel better. | $61M / Series B / Aug 11, 2021 | |
|
Naveris
|
Naveris is a biotechnology company that provides highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission. The company's 3D biomimetic technology replicates themorphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, its technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients.Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts. | Series A / Dec 15, 2020 | |
Tremeau Pharmaceuticals
|
Tremeau Pharmaceuticals is a Massachusetts based privately funded clinical stage company focused on commercializing non-opioid pain therapies targeting serious rare diseases impacted by the cyclooxygenase (COX) or prostanoid pathways. They focus exclusively on orphan or unique disease states with high unmet medical need. | Private Equity / Dec 09, 2020 | |
Zikani Therapeutics
|
Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others,especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides.The company was founded in 2014 and is headquartered in Newton, Massachusetts. | $7.5M / Series A / Apr 20, 2020 | |
|
Alladapt Immunotherapeutics
|
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens. | $60M / Series C / Feb 20, 2020 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Gurnet Point Capital invest in?
Gurnet Point Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gurnet Point Capital?
Public channels for Gurnet Point Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Gurnet Point Capital?
The team at Gurnet Point Capital includes David Moore (Partner), Michael Vigilante (Principal) and Alex Tsoukas (Principal), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
